AZD8421
AZD8421 is a selective CDK2 inhibitor (IC50 = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer[1].
Product Specifications
CAS Number
3047321-53-6
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd8421.html
Concentration
10mM
Purity
99.60
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCN1C=NC2=C1N=C(N[C@@H](CC)[C@@H](C)O)N=C2N[C@@H]3CN(S(=O)(NCC)=O)CC3
Molecular Formula
C18H32N8O3S
Molecular Weight
440.56
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ATRX / RAD54 (Alpha Thalassemia Mental Retardation) (23c), CF647 conjugate, 0.1mg/mL
SSX2 (SSX2B) (NM_001164417) Human Over-expression Lysate
Colloidal Gold Conjugated Goat Affinity Purified Antibody to Human Kappa (Free & Bound), 10nm
